In systematic reviews, single doses of sucrose have been reported to reduce pain in newborns undergoing commonly performed medical procedures, including heel-lancing and venipuncture. 11, 12 Based on these data, national and international pain management guidelines promote the widespread use of sucrose. [13] [14] [15] [16] However, sucrose has not been evaluated for all commonly performed procedures in healthy term newborns, and there are concerns that sucrose may raise blood glucose levels in newborns of diabetic mothers. It is necessary to demonstrate that sucrose is effective and safe for varied procedures, repeated use and diverse infant populations.
We sought to evaluate the effectiveness and safety of sucrose in newborns of diabetic mothers and nondiabetic moth-ers undergoing routine painful medical procedures during the first 2 days after birth. Our hypothesis was that sucrose reduces pain during intramuscular injection of vitamin K, venipuncture for the newborn screening test and heel lance for blood glucose monitoring without serious adverse effects.
Methods

Study design and population
We conducted a double-blind randomized controlled trial at Mount Sinai Hospital, Toronto, Ontario. We recruited participants between Sept. 15, 2003, and July 27, 2004 . We included healthy newborns (≥ 36 weeks gestation) born to nondiabetic mothers with uneventful pregnancies or to diabetic mothers (type 1, type 2, or gestational diabetes that was controlled by diet or insulin). We identified eligible newborns from the daily logs in the delivery suite. We excluded newborns with major congenital or neurologic anomalies, or clinical diagnoses of birth asphyxia 17 or seizures. We also excluded newborns admitted to the neonatal intensive care unit, those who received analgesics or sedatives or both, and those who were scheduled to undergo circumcision during the study period.
This study was approved by the research ethics boards of Mount Sinai Hospital, The Hospital for Sick Children and York University, Toronto, Ontario, as well as Health Canada. A member of the study team obtained written consent to participate from the parents before the birth of the newborn.
Intervention
Newborns received 2 mL of a 24%-sucrose solution 11 or 2 mL of sterile water (placebo) by mouth before all intramuscular injections, venipunctures and heel-lances performed within 2 days of birth. Beginning 2 minutes before the procedure, the nurse assigned to each newborn used a syringe to administer sucrose or placebo to the anterior surface of the tongue over a period of about 60 seconds. All procedures were performed by certified nurses or physicians, as per standard practices at the study centre.
Concealment of allocation
Concealment of allocation was achieved by carrying out randomization and dispensing functions off-site. Using a random numbers table and allocation ratio of 1:1 for sucrose and placebo, a research pharmacist at The Hospital for Sick Children prepared 2 separate block-randomization assignments (1 for newborns of diabetic mothers and 1 for newborns of nondiabetic mothers). Respironics (Murrysville, Pennsylvania) provided single-use sucrose (Sweet-Ease) and placebo packages that appeared identical. The solutions were labelled with each newborn's name and stored in patient-specific plastic bags in the newborn's medication bin. The study personnel, health care workers and parents did not know which newborns received sucrose. The success of blinding was not evaluated.
Pain outcomes
The primary outcome measure was pain. We videotaped all newborns during intramuscular injection of vitamin K performed in the first hour after birth and during a venipuncture performed after at least 24 hours for the newborn screening test. As well, we videotaped newborns of diabetic mothers during the first 3 heel-lances that were performed within the first 12 hours after birth as part of the glucose monitoring protocol at the study centre.
About 5 minutes before each procedure, a portable pulse oximeter was applied to the newborn's foot or hand, and a digital video camera was mounted on a tripod 1 metre from the newborn's body. Throughout the procedure, we videotaped the newborn's face and recorded his or her physiologic responses (heart rate, oxygen saturation). All newborns were in a supine position and were partially swaddled (the limb that was used for the procedure was exposed). Parents were present during the procedure but did not touch or interact with their newborn.
We assessed pain using a validated composite pain measure (Premature Infant Pain Profile). 18 This profile includes 3 facial actions (brow bulge, eyes squeezed shut, nasolabial furrow), and 2 physiologic (heart rate, oxygen saturation) and 2 contextual (gestational age, infant state) indices of pain. Using the videotaped images, a research assistant who was unaware of treatment allocation, study hypotheses and whether the newborn was from a diabetic or nondiabetic mother scored each facial action as present or absent in 2-second intervals for the first 30 seconds of the venipuncture. For intramuscular injection and heel lances, which were of shorter duration, only facial actions during the first 20 seconds were scored (or less if the procedure lasted less than 20 seconds). The percentage of the total time that each facial action was observed during each phase was calculated. For physiologic data, changes in heart rate and oxygen saturation from baseline were recorded over the same period. Using established methods, 18 we calculated total Premature Infant Pain Profile scores for each procedure by summing the scores of the 7 indicators. Scores ranged from 0 (no pain) to 18 (maximum pain). We assessed inter-rater reliability by having a second rater score 28% of the procedures; the intraclass correlation coefficient was 0.97 (95% confidence interval [CI] 0.96 to 0.98).
Safety outcomes
The adverse events monitored over the course of the study included spitting up within 30 minutes of medication being administered and blood glucose levels (among newborns of diabetic mothers only). A safety committee was convened to oversee serious adverse events (aspiration, prolonged desaturation).
Sample size calculation and statistical analysis
We based the sample size calculation on a clinically important difference of 20% in pain scores between the sucrose and placebo groups. 19 Using previous data, 2, 20 we translated this to a moderate effect size (0.6) and a sample size of 45 newborns per group (total sample size = 90). 21 We doubled the sample size to 180 newborns because we planned to include 2 groups of newborns (those from diabetic and nondiabetic mothers) and increased the sample size to 240 to account for potential missing data and drop-outs. Thus, we included 60 newborns in each study group (newborns of diabetic mothers given sucrose, newborns of diabetic mothers given placebo, newborns of nondiabetic mothers given sucrose, newborns of nondiabetic mothers given placebo).
Research
In our primary analysis, we compared the average of all pain scores for each newborn in the sucrose and placebo groups using the Student t test. Using this test, we separately compared pain scores between those who received sucrose and those who received a placebo for each group (newborns of diabetic or nondiabetic mothers) and for each procedure (intramuscular injection, venipuncture). We analyzed pain scores during the first 3 heel lances in newborns of diabetic mothers using a repeatedmeasures linear mixed-model analysis of variance.
We performed post-hoc analyses after adjusting for baseline characteristics (sex, mode of delivery, drugs given during delivery, gestational age, postnatal age) by use of a general linear model (for intramuscular injection and venipuncture) and a linear mixed-model analysis (for heel-lances). For newborns of diabetic mothers, we also included indices of maternal illness (type of diabetes, use of insulin, glycosylated he-
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moglobin concentration) and newborn blood glucose level at the time of the procedure (for heel-lances). We analyzed adverse events using the χ 2 test or the Student t test. An intentto-treat approach was used that included all infants with data. A p value of 0.05 or less was considered significant.
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Results
Recruitment and withdrawals
In total, we approached 412 parents, 263 of whom agreed to participate. Twenty-three newborns were not randomized;
6 had an unstable condition at birth and were withdrawn, and 17 were missed by study personnel. In total, 240 newborns were included in our study (120 in the sucrose group and 120 in the placebo group) (Figure 1 ).
Birth characteristics and treatment-related factors
Birth characteristics are shown in Table 1 . Newborns of diabetic mothers received more heel lances before venipuncture and therefore received more doses of study medication (mean 6.4, standard deviation [SD] 2.0) than newborns of nondiabetic mothers (mean 2.3, SD 0.8) (p < 0.001).
Pain response
Our primary analysis showed that the overall mean score for the Premature Infant Pain Profile was significantly lower among newborns who received sucrose (mean score 6.8, SD 2.9) than among those who received a placebo (mean score 8. 
Characteristics
Newborns of nondiabetic mothers n = 60
Newborns of diabetic mothers n = 60
At birth
Gestational age, wk 39.1 (1. †The Apgar score was used to assess newborn health. Scores are based on 5 criteria (appearance, pulse, grimace, activity, respiration) and range from 0 to 10. A score over 7 is generally considered to be healthy.
At heel lance
(mean difference -1.3, 95% CI -2.0 to -0.6, p < 0.001). Pain scores during intramuscular injection, venipuncture and heel-lance (newborns of diabetic mothers only) are shown in Table 2 . Pain scores during intramuscular injection did not differ between the sucrose and placebo groups for newborns of nondiabetic mothers (mean score 7.4, 95% CI 6.4-8.4 v. mean score 8.5, 95% CI 7.6-9.3, p = 0.10) or diabetic mothers (mean score 6.2, 95% CI 5.2-7.2 v. mean score 7.2, 95% CI 6.3-8.2, p = 0.15). During venipuncture, pain scores were significantly lower among newborns of nondiabetic mothers who received sucrose compared with those who received a placebo (mean score 5.7, 95% CI 4.7-6.7 v. mean score 8.9, 95% CI 7.9-9.9, p < 0.001). This was consistent among newborns of diabetic mothers (sucrose group: mean score 6.8, 95% CI 5.7-7.9 v. placebo: mean score 9.2, 95% CI 8.4-10.1, p < 0.001). Among newborns of diabetic mothers, the pain scores during the first 3 heel lances did not differ between the sucrose and placebo groups.
Post-hoc analyses that adjusted for baseline characteristics did not change the pattern of the results.
Adverse effects
Among newborns of nondiabetic mothers, more newborns in the placebo group spat up (p = 0.04). Among newborns of diabetic mothers, there was no difference in the incidence of minor adverse effects or mean blood glucose levels between those who received sucrose or placebo (Table 3 ). There were no serious adverse events during the study.
Interpretation
We found that sucrose reduced overall pain in newborns when administered before painful medical procedures during the first 2 days after birth. The observed difference in pain, however, was modest (16%) and did not meet our a priori definition of a clinically important difference of 20%. 19 When we analyzed each procedure separately for newborns of diabetic and nondiabetic mothers, the results were consistent between the 2 groups of newborns but the results were inconsistent between procedures. In both newborn groups, sucrose was effective for reducing pain during venipuncture for the newborn screening test, but it was ineffective during intramuscular injection of vitamin K. In addition, sucrose was ineffective for reducing pain in newborns of diabetic mothers during repeated heel-lances.
Our observation that sucrose reduces pain during venipuncture is consistent with previous research involving term newborns. 22 Unexpectedly, we did not observe analgesic effects during either intramuscular injection of vitamin K in either group or during repeated heel-lancing for blood glucose monitoring in newborns of diabetic mothers. In contrast, previous studies reported analgesic effects in newborns undergoing heel lancing 12 and in older infants undergoing intramuscular injections of vaccines. [23] [24] [25] To rule out an effect of baseline newborn and maternal characteristics on the effectiveness of sucrose, we performed post-hoc analyses adjusted for birth characteristics. Among newborn of diabetic mothers, we also adjusted for indices of illness. We found no significant effects of any of these factors on the effectiveness of sucrose, which strengthens our interpretation of the results.
The observed ineffectiveness of sucrose during intramuscular injection and heel lances may be because of newborn postnatal age, method of pain assessment, and procedure technique. In our study, all procedures except for venipuncture were performed within 12 hours of birth. In contrast, previous studies have reported the effects of sucrose beyond 1 day of birth. 12 Significant concentrations of endogenous opioids (β-endorphin) are present in newborns during birth adaptation in the first hours after birth. 26, 27 It is possible that sucrose did not offer any additional benefit above physiologic Note: CI = confidence interval. *Pain was measured using the Premature Infant Pain Profile, which includes 7 indicators of pain (brow bulge, eyes squeezed shut, nasolabial furrow, gestational age, infant state, and changes in heart rate and oxygen saturation from baseline). †Pain scores during intramuscular injection and venipuncture were compared between groups using the Student t test. ‡Pain scores during heel lances were compared using mixed-model analysis. §Mean difference (95% CI) refers to overall value. levels of β-endorphin. The analgesic effect of sucrose may also depend on when pain is assessed. In the present study, we measured pain during the procedure, whereas other studies assessed pain for up to several minutes afterward. 12 Sucrose may be a relatively weak analgesic 28 that is more effective at calming infants during the recovery period after a painful procedure than during the actual procedure when pain is at its peak. 29 Finally, we used a fully retractable automatic lancet during the heel-lances and collected only a single drop of blood. This resulted in minimal pain in newborns, 18 which was perhaps too low for sucrose to have a measurable effect.
Research
There is debate about the use of placebos and the ethics of withholding treatment in clinical trials evaluating analgesics. 30 It is important, however, that the benefits of an analgesic be established before it becomes the standard of care. Sucrose is quickly becoming the standard of care in nurseries 31 because of the ease of administration, affordability and perceived safety and efficacy. It is even replacing established analgesics such as opioids and local anesthetics. 32 We used a placebocontrolled design in our study because of unanswered questions about the effectiveness of sucrose for different procedures and when used repeatedly, and because the official standard of care at our institution did not include sucrose or any other analgesic intervention. Although our results show that sucrose is relatively safe, its effectiveness in the first 2 days after birth is limited and cannot be extrapolated from one painful procedure to another.
The present study has several strengths, including its large sample size and double-blind randomized design. Even for a medium effect size of 0.4, we had greater than 95% power to detect a difference using a repeated-measures design with α = 0.05. Moreover, our results are generalizable to most clinical settings because we included a diverse infant population and the most commonly performed procedures, and because we used a "real world" approach that included multiple nurses and physicians administering study medications and performing procedures.
However, a limitation of our study is that we may have increased variability in pain responses by unsettling the newborns with the application of physiologic monitors. In addition, our pain assessment tool, the Premature Infant Pain Profile, may not have adequately captured infant pain. However, that it is the best validated measure of pain in newborns. 7 Our results are limited to the effectiveness of sucrose when administered as the sole analgesic agent. Pain relief is enhanced when sucrose is combined with a pacifier, 16 but our hospital disallowed the use of pacifiers for the present study because of baby-friendly initiatives designed to encourage breast-feeding. Other institutions have similar practices. 31 In conclusion, we found a modest 16% reduction in overall pain among newborns of both diabetic and nondiabetic mothers when sucrose was used repeatedly for all procedures performed in the first 2 days after birth. Moreover, when we evaluated each procedure separately, the effectiveness of sucrose was limited to venipuncture. Based on these results, we recommend using sucrose to reduce pain in newborns undergoing venipuncture for the newborn screening test but not for intramuscular injection of vitamin K. In addition, sucrose is not recommended for heel lances for glucose monitoring in newborns of diabetic mothers. Current pain management guidelines should be updated to reflect the results of the present study. Further studies are needed to elucidate the mechanisms responsible for the ineffectiveness of sucrose immediately after birth.
